Cargando…
MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways
Gefitinib is a tyrosine kinase inhibitor that has been used for the treatment of non-small-cell lung carcinoma (NSCLC). The ability of miR-7 to enhance gefitinib-induced cytotoxicity in NSCLC cells was evaluated in this study. We found that miR-7 significantly decreased the IC50 of gefitinib and inh...
Autores principales: | Zhao, Jun-gang, Men, Wan-fu, Tang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631286/ https://www.ncbi.nlm.nih.gov/pubmed/26557760 http://dx.doi.org/10.5114/wo.2015.52655 |
Ejemplares similares
-
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan, Yong-hong, et al.
Publicado: (2018) -
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
por: Garofalo, Michela, et al.
Publicado: (2011) -
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Sin, Thomas K., et al.
Publicado: (2016) -
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020) -
let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer
por: Yin, Jun, et al.
Publicado: (2019)